Retatrutide Dosage Chart & Escalation Schedule (Research Reference)

Retatrutide dose arms in the Phase 2 obesity trial

The pivotal 48-week Phase 2 obesity study tested maintenance doses of 1 mg, 4 mg, 8 mg and 12 mg given subcutaneously once weekly, plus placebo. Higher-dose groups used a lower 2 mg or 4 mg starting dose and four-week escalation intervals. The protocol did not use one universal staircase in which every participant passed through every listed dose.

Why trials used dose escalation

Gastrointestinal adverse events were dose-related and occurred most often during dose escalation. In the Phase 2 obesity trial, a lower starting dose partially mitigated these events. Escalation was therefore a controlled study-design feature used to evaluate tolerability—not evidence that a similar pattern is safe outside a trial.

Later Phase 3 programs use protocol-defined target doses and escalation rules that differ by study. Public registry records may intentionally mask exact dose details while a trial is underway. A protocol from one trial should not be reconstructed into personal instructions.

Dosing frequency in research

Published trials administered retatrutide once weekly by subcutaneous injection. Study teams controlled product identity, concentration, storage, administration, monitoring and dose adjustments. Those safeguards are part of the intervention and cannot be reproduced by knowing a milligram value alone.

Why there is no personal dosage chart

An approved dosage is determined through regulatory review of efficacy, safety, manufacturing consistency, labeling and risk management. Retatrutide has not completed that process. Materials described online as research compounds are not an approved substitute for a clinical-trial product, and their identity or concentration cannot be assumed.

For this reason, The Retatrutide Guide does not convert trial arms into injection instructions or provide storage and reconstitution procedures for unapproved material.